Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in [more]
TKIs are involved in treating an increasing number of cancer indications. Doctors need to be aware of the range of potentially serious side effects associated with these drugs, and know how to mitigate them, to [more]
Targeted therapies seek to close down signalling pathways that allow tumours to prosper. But these pathways may also be vital to other clinical functions. With rising concern about collateral cardiac damage from cancer treatment comes [more]